{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T04:01:36Z","timestamp":1793678496284,"version":"4.5.1"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100018617","name":"Liaoning Revitalization Talents Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018617","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018559","name":"Shenyang Young and Middle-aged Science and Technology Innovation Talent Support Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018559","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.bmc.2024.117725","type":"journal-article","created":{"date-parts":[[2024,4,14]],"date-time":"2024-04-14T01:52:11Z","timestamp":1713059531000},"page":"117725","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Discovery of novel pyridone-benzamide derivatives possessing a 1-methyl-2-benzimidazolinone moiety as potent EZH2 inhibitors for the treatment of B-cell lymphomas"],"prefix":"10.1016","volume":"105","author":[{"given":"Di","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyi","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanhao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingze","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2024.117725_b0005","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.957170","article-title":"Gastric DLBCL clonal evolution as function of patient age","volume":"13","author":"Iosselevitch","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.bmc.2024.117725_b0010","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJMra2027612","article-title":"Salles G Diffuse Large B-Cell Lymphoma","volume":"384","author":"Sehn","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmc.2024.117725_b0015","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s40259-021-00491-w","article-title":"Herrera A F Advances in Immunotherapy for Diffuse Large B Cell Lymphoma","volume":"35","author":"Shouse","year":"2021","journal-title":"BioDrugs"},{"key":"10.1016\/j.bmc.2024.117725_b0020","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1586\/17474086.2015.1061427","article-title":"Ibrutinib for the treatment of Waldenstrom macroglobulinemia","volume":"8","author":"Chakraborty","year":"2015","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.bmc.2024.117725_b0025","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13045-019-0814-6","article-title":"Chng W J EZH2 abnormalities in lymphoid malignancies: underlying mechanisms and therapeutic implications","volume":"12","author":"Li","year":"2019","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.bmc.2024.117725_b0030","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/nature04431","article-title":"The Polycomb group protein EZH2 directly controls DNA methylation","volume":"439","author":"Vire","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2024.117725_b0035","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.mrfmmm.2008.07.010","article-title":"Lange C A Roles of the EZH2 histone methyltransferase in cancer epigenetics","volume":"647","author":"Simon","year":"2008","journal-title":"Mutat Res"},{"key":"10.1016\/j.bmc.2024.117725_b0040","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/ng.518","article-title":"Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin","volume":"42","author":"Morin","year":"2010","journal-title":"Nat Genet"},{"key":"10.1016\/j.bmc.2024.117725_b0045","doi-asserted-by":"crossref","first-page":"20980","DOI":"10.1073\/pnas.1012525107","article-title":"Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas","volume":"107","author":"Sneeringer","year":"2010","journal-title":"PNAS"},{"key":"10.1016\/j.bmc.2024.117725_b0050","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/bjc.2011.551","article-title":"Hung M C The role of EZH2 in tumour progression","volume":"106","author":"Chang","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.bmc.2024.117725_b0055","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.amjmed.2021.03.034","article-title":"Cooper-DeHoff R M New Drugs Approved in 2020","volume":"134","author":"Ebied","year":"2021","journal-title":"Am J Med"},{"key":"10.1016\/j.bmc.2024.117725_b0060","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1007\/s40265-022-01800-5","article-title":"Tosilate: First Approval","volume":"82","author":"Valemetostat","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.bmc.2024.117725_b0065","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1182\/blood-2021-146657","article-title":"Pivotal Phase 2 Study of the EZH1 and EZH2 Inhibitor Valemetostat Tosylate (DS-3201b) in Patients with Relapsed or Refractory Adult T-Cell Leukemia\/Lymphoma","volume":"138","author":"Yoshimitsu","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.bmc.2024.117725_b0070","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1021\/acs.jmedchem.7b01375","volume":"61","author":"Kung","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117725_b0075","doi-asserted-by":"crossref","first-page":"8895","DOI":"10.1021\/acs.jmedchem.8b01136","article-title":"Optimization of a Series of Mu Opioid Receptor (MOR) Agonists with High G Protein Signaling Bias","volume":"61","author":"Kennedy","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117725_b0080","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1016\/j.bmc.2017.06.014","article-title":"Novel 3H-[1,2,3]triazolo[4,5-c]pyridine derivatives as GPR119 agonists: Synthesis and structure-activity\/solubility relationships","volume":"25","author":"Matsuda","year":"2017","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2024.117725_b0085","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1021\/acs.jmedchem.5b01501","article-title":"The Importance of Being Me: Magic Methyls, Methyltransferase Inhibitors, and the Discovery of Tazemetostat","volume":"59","author":"Kuntz","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117725_b0090","doi-asserted-by":"crossref","first-page":"15170","DOI":"10.1021\/acs.jmedchem.1c01154","article-title":"Discovery of IHMT-EZH2-115 as a Potent and Selective Enhancer of Zeste Homolog 2 (EZH2) Inhibitor for the Treatment of B-Cell Lymphomas","volume":"64","author":"Zhou","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117725_b0095","doi-asserted-by":"crossref","first-page":"11384","DOI":"10.1038\/ncomms11384","article-title":"Polycomb repressive complex 2 structure with inhibitor reveals a mechanism of activation and drug resistance","volume":"7","author":"Brooun","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmc.2024.117725_b0100","doi-asserted-by":"crossref","first-page":"32646","DOI":"10.18632\/oncotarget.5066","article-title":"Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors","volume":"6","author":"Baker","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.bmc.2024.117725_b0105","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/onc.2015.114","article-title":"Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors","volume":"35","author":"Gibaja","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.bmc.2024.117725_b0110","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s11899-018-0466-6","article-title":"Amengual J E Emerging EZH2 Inhibitors and Their Application in Lymphoma","volume":"13","author":"Lue","year":"2018","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.bmc.2024.117725_b0115","doi-asserted-by":"crossref","first-page":"7772","DOI":"10.1021\/jm200893p","article-title":"Metabolism-Directed Design of Oxetane-Containing Arylsulfonamide Derivatives as \u03b3-Secretase Inhibitors","volume":"54","author":"Stepan","year":"2011","journal-title":"J Med Chem"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089624001391?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089624001391?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T18:32:57Z","timestamp":1714761177000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089624001391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":23,"alternative-id":["S0968089624001391"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2024.117725","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of novel pyridone-benzamide derivatives possessing a 1-methyl-2-benzimidazolinone moiety as potent EZH2 inhibitors for the treatment of B-cell lymphomas","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2024.117725","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"117725"}}